Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts
- Author:
Jun Ho YI
1
;
Seong Hyun JEONG
;
Seok Jin KIM
;
Dok Hyun YOON
;
Hye Jin KANG
;
Youngil KOH
;
Jin Seok KIM
;
Won-Sik LEE
;
Deok-Hwan YANG
;
Young Rok DO
;
Min Kyoung KIM
;
Kwai Han YOO
;
Yoon Seok CHOI
;
Whan Jung YUN
;
Yong PARK
;
Jae-Cheol JO
;
Hyeon-Seok EOM
;
Jae-Yong KWAK
;
Ho-Jin SHIN
;
Byeong Bae PARK
;
Seong Yoon YI
;
Ji-Hyun KWON
;
Sung Yong OH
;
Hyo Jung KIM
;
Byeong Seok SOHN
;
Jong Ho WON
;
Dae-Sik HONG
;
Ho-Sup LEE
;
Gyeong-Won LEE
;
Cheolwon SUH
;
Won Seog KIM
Author Information
- Publication Type:Original Article
- From:Cancer Research and Treatment 2023;55(1):325-333
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:Diffuse large B-cell lymphoma (DLBCL) is the most common hematologic malignancy worldwide. Although substantial improvement has been achieved by the frontline rituximab-based chemoimmunotherapy, up to 40%-50% of patients will eventually have relapsed or refractory disease, whose prognosis is extremely dismal.
Materials and Methods:We have carried out two prospective cohort studies that include over 1,500 DLBCL patients treated with rituximab plus CHOP (#NCT01202448 and #NCT02474550). In the current report, we describe the outcomes of refractory DLBCL patients. Patients were defined to have refractory DLBCL if they met one of the followings, not achieving at least partial response after 4 or more cycles of R-CHOP; not achieving at least partial response after 2 or more cycles of salvage therapy; progressive disease within 12 months after autologous stem cell transplantation.
Results:Among 1,581 patients, a total of 260 patients met the criteria for the refractory disease after a median time to progression of 9.1 months. The objective response rate of salvage treatment was 26.4%, and the complete response rate was 9.6%. The median overall survival (OS) was 7.5 months (95% confidence interval, 6.4 to 8.6), and the 2-year survival rate was 22.1%±2.8%. The median OS for each refractory category was not significantly different (p=0.529).
Conclusion:In line with the previous studies, the outcomes of refractory DLBCL patients were extremely poor, which necessitates novel approaches for this population.
